Biomarkers for therapy selection in metastatic urothelial cancer

导出学术成果认领

摘要The treatment of metastatic urothelial cancer (mUC) has been transformed by recent progress in clinical trials and drug development. There are now three therapeutic classes with proven benefits in mUC: chemotherapy, immunotherapy, and targeted therapy. The optimal sequence and combination of these classes remain to be defined. Biomarker development is essential to guide treatment selection at each therapeutic juncture. Two biomarkers, programmed death-ligand 1 expression and fibroblast growth factor receptor alterations, have been incorporated into the mUC treatment paradigm thus far. This review discusses predictive biomarkers in development and their potential to influence mUC treatment selection moving forward.

作者 Tomi Jun ^[1] Jonathan Anker ^[2] Matthew D.Galsky ^[2] 学术成果认领

作者单位 Division of Hematology and Medical Oncology,Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,New York,NY 10029,USA;Medical Sciences,Sema4,Stamford,CT 06902,USA ^[1] Division of Hematology and Medical Oncology,Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,New York,NY 10029,USA ^[2]

关键词 Metastatic urothelial cancer biomarkers immunotherapy chemotherapy targeted therapy antibody-drug conjugates

栏目名称 Review

DOI 10.20517/2394-4722.2021.171

发布时间 2022-05-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交